This company has been marked as potentially delisted and may not be actively trading. Bioblast Pharma (ORPN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ORPN vs. VCNX, SYRS, EVFM, GRTX, VAXX, ASLN, ATHX, HEPA, PTPI, and BPTSYShould you be buying Bioblast Pharma stock or one of its competitors? The main competitors of Bioblast Pharma include Vaccinex (VCNX), Syros Pharmaceuticals (SYRS), Evofem Biosciences (EVFM), Galera Therapeutics (GRTX), Vaxxinity (VAXX), ASLAN Pharmaceuticals (ASLN), Athersys (ATHX), Hepion Pharmaceuticals (HEPA), Petros Pharmaceuticals (PTPI), and Biophytis (BPTSY). These companies are all part of the "medical" sector. Bioblast Pharma vs. Its Competitors Vaccinex Syros Pharmaceuticals Evofem Biosciences Galera Therapeutics Vaxxinity ASLAN Pharmaceuticals Athersys Hepion Pharmaceuticals Petros Pharmaceuticals Biophytis Vaccinex (NASDAQ:VCNX) and Bioblast Pharma (NASDAQ:ORPN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk. Do institutionals and insiders believe in VCNX or ORPN? 50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 4.5% of Bioblast Pharma shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor VCNX or ORPN? In the previous week, Vaccinex's average media sentiment score of 0.00 equaled Bioblast Pharma'saverage media sentiment score. Company Overall Sentiment Vaccinex Neutral Bioblast Pharma Neutral Is VCNX or ORPN more profitable? Company Net Margins Return on Equity Return on Assets VaccinexN/A N/A -383.58% Bioblast Pharma N/A N/A N/A Which has better earnings & valuation, VCNX or ORPN? Bioblast Pharma has lower revenue, but higher earnings than Vaccinex. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaccinex$388K3.42-$20.25M-$48.27-0.01Bioblast PharmaN/AN/A-$5.94MN/AN/A Which has more risk and volatility, VCNX or ORPN? Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Bioblast Pharma has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. SummaryVaccinex and Bioblast Pharma tied by winning 3 of the 6 factors compared between the two stocks. Get Bioblast Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORPN vs. The Competition Export to ExcelMetricBioblast PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$494K$984.59M$6.07B$10.42BDividend YieldN/A4.84%5.66%4.69%P/E RatioN/A1.2785.5326.92Price / SalesN/A30.58588.18180.92Price / CashN/A17.6438.3262.20Price / Book0.167.3112.776.64Net Income-$5.94M-$7.96M$3.30B$275.87M Bioblast Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORPNBioblast PharmaN/A$1.18+0.4%N/A-20.9%$494KN/A0.00N/AHigh Trading VolumeVCNXVaccinex0.755 of 5 stars$0.64+3.2%N/A-71.7%$1.66M$388K-0.0140Gap DownSYRSSyros Pharmaceuticals3.7504 of 5 stars$0.01+4,900.0%$1.00+19,900.0%-99.7%$1.65M$386K0.00120Gap UpEVFMEvofem Biosciences0.4624 of 5 stars$0.01-3.7%N/A+8.2%$1.61M$11.39M-0.02120Gap UpGRTXGalera TherapeuticsN/A$0.02+0.5%N/A-75.7%$1.44MN/A-0.0530VAXXVaxxinityN/A$0.01+9,900.0%N/A-95.0%$1.27MN/A-0.0290Gap UpASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330ATHXAthersysN/AN/AN/AN/A$833K$146K0.0024Gap UpHEPAHepion Pharmaceuticals0.1095 of 5 stars$0.07+4.6%N/A-99.7%$787KN/A-0.0220Gap DownPTPIPetros PharmaceuticalsN/A$0.02+1.6%N/A-99.7%$770K$5.11M-0.0120Gap DownBPTSYBiophytisN/A$2.00flatN/A-51.7%$702KN/A0.0030 Related Companies and Tools Related Companies Vaccinex Competitors Syros Pharmaceuticals Competitors Evofem Biosciences Competitors Galera Therapeutics Competitors Vaxxinity Competitors ASLAN Pharmaceuticals Competitors Athersys Competitors Hepion Pharmaceuticals Competitors Petros Pharmaceuticals Competitors Biophytis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORPN) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersWhy This Titanium Explorer Caught Rio Tinto’s EyeAs U.S. defense spending crosses $1 trillion, drones, hypersonics, and next-gen aerospace are taking center st...Capital Trends | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBetter than Bitcoin?Bitcoin’s historic run may be ending — and Weiss Ratings’ Juan Villaverde, who’s nailed every major crypto bul...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioblast Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
